Asahi Kasei Therapeutics starts Japan Phase II trial of Cresemba in pediatric patients
Reuters2026/09/14 02:04- Asahi Kasei Therapeutics started a Phase II trial in Japan of isavuconazonium sulfate (Cresemba) for pediatric patients aged 1 to 17.
- Study targets children at risk of deep mycoses, assessing safety profile, pharmacokinetics.
- Cresemba remains unapproved for pediatric use in Japan despite pediatric clearances in several overseas markets.
- Asahi Kasei Therapeutics holds Japan rights; adult Cresemba gained Japan clearance in December 2022, with a 40 mg capsule added in September 2024.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GE HealthCare (GEHC.US) plans to acquire Sofie for $1 billion, aiming for high growth in the radiopharmaceutical sector
GE Healthcare plans to acquire Sofie for about $1 billion, aiming to expand recurring revenue by combining imaging devices with radiodiagnostic agents, in response to weak stock performance and pressure from activist investors.
Silver Price Forecast: XAG/USD bears have the upper hand below $64.75-$64.85 confluence
Resonac Holdings says RESONAC REPORT 2026 integrated report now available
Japanese Yen edges lower vs USD amid Middle East jitters as Fed, BoJ meetings loom
Crypto prices
More
